Animal data: The contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo

Advanced Drug Delivery Reviews

Volumn 59, Issue 11, 2007, Pages 1103-1120

  Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Absorption prediction; ADME; Bioavailability; Biopharmaceutics classification system; Human intestinal absorption; Intestinal efflux; Intestinal permeability; Model correlations; P glycoprotein; Pharmacokinetics

Indexed keywords

MAMMALS; MOLECULAR STRUCTURE; PHARMACODYNAMICS; TOXICITY;

ABSORPTION PREDICTION; ADME; BIOAVAILABILITY; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; HUMAN INTESTINAL ABSORPTION; INTESTINAL EFFLUX; INTESTINAL PERMEABILITY; MODEL CORRELATIONS; P GLYCOPROTEIN;

DRUG DELIVERY;

AMANTADINE; AMILORIDE; AMOXICILLIN; ATENOLOL; BENDROFLUMETHIAZIDE; CAPTOPRIL; CARBAMAZEPINE; CARISOPRODOL; CHLORPROTHIXENE; CHLORZOXAZONE; CIMETIDINE; ERYTHROMYCIN; FENOFIBRATE; FLUPENTIXOL; FOLIC ACID; GLIPIZIDE; HYDROCHLOROTHIAZIDE; LEVODOPA; LEVOTHYROXINE; MECLOZINE; METHYLDOPA; METOCLOPRAMIDE; PHENAZONE; PREDNISONE; SULINDAC; TERFENADINE; TETRACYCLINE; THIAMAZOLE; TINIDAZOLE; UNINDEXED DRUG;

BIOLOGICAL MODEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; GASTROINTESTINAL TRACT; HUMAN; IN VIVO STUDY; JEJUNUM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; INTESTINAL ABSORPTION; JEJUNUM; MODELS, ANIMAL; PERFUSION; PERMEABILITY; RATS; SPECIES SPECIFICITY;

EID: 35349012642     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.06.016     Document Type: Review

References (145)

1. van de Waterbeemd H., and Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2 (2003) 192-204
2. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715
3. Schmid E.F., and Smith D.A. R&D technology investments: misguided and expensive or a better way to discover medicines?. Drug Discov. Today 11 (2006) 775-784
4. Skold C., Winiwarter S., Wernevik J., Bergstrom F., Engstrom L., Allen R., Box K., Comer J., Mole J., Hallberg A., Lennernas H., Lundstedt T., Ungell A.L., and Karlen A. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J. Med. Chem. 49 (2006) 6660-6671
5. Luder K., Lindfors L., Westergren J., Nordholm S., and Kjellander R. In silico prediction of drug solubility: 2. Free energy of solvation in pure melts. J. Phys. Chem., B 111 (2007) 1883-1892
6. Winiwarter S., Bonham N.M., Ax F., Hallberg A., Lennernas H., and Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41 (1998) 4939-4949
7. Palm K., Stenberg P., Luthman K., and Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997) 568-571
8. Bergstrom C.A., Wassvik C.M., Norinder U., Luthman K., and Artursson P. Global and local computational models for aqueous solubility prediction of drug-like molecules. J. Chem. Inf. Comput. Sci. 44 (2004) 1477-1488
9. Afzelius L., Raubacher F., Karlen A., Jorgensen F.S., Andersson T.B., Masimirembwa C.M., and Zamora I. Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques. Drug Metab. Dispos. 32 (2004) 1218-1229
10. Kratochwil N.A., Huber W., Muller F., Kansy M., and Gerber P.R. Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol. 64 (2002) 1355-1374
11. Afzelius L., Arnby C.H., Broo A., Carlsson L., Isaksson C., Jurva U., Kjellander B., Kolmodin K., Nilsson K., Raubacher F., and Weidolf L. State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications. Drug Metab. Rev. 39 (2007) 61-86
12. Mager D.E. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv. Drug Deliv. Rev. 58 (2006) 1326-1356
13. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
14. Bergman E., Forsell P., Persson E.M., Knutson L., Dickinson P., Smith R., Swaisland H., Farmer M.R., Cantarini M.V., and Lennernas H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int. J. Pharm. (2007) 17482782 (PMID)
15. Bonlokke L., Hovgaard L., Kristensen H.G., Knutson L., and Lennernas H. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur. J. Pharm. Sci. 12 (2001) 239-250
16. Bonlokke L., Hovgaard L., Kristensen H.G., Knutson L., Lindahl A., and Lennernas H. A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. Eur. J. Pharm. Sci. 8 (1999) 19-27
17. Bredberg E., Lennernas H., and Paalzow L. Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration. Pharm. Res. 11 (1994) 549-555
18. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42 (2003) 1141-1160
19. Lennernas H. Intestinal drug absorption and bioavailability: beyond involvement of single transport function. J. Pharm. Pharmacol. 55 (2003) 429-433
20. Lennernas H., and Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 57 (2005) 273-285
21. Lennernas H., Ahrenstedt O., Hallgren R., Knutson L., Ryde M., and Paalzow L.K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9 (1992) 1243-1251
22. Takamatsu N., Welage L.S., Idkaidek N.M., Liu D.Y., Lee P.I., Hayashi Y., Rhie J.K., Lennernas H., Barnett J.L., Shah V.P., Lesko L., and Amidon G.L. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm. Res. 14 (1997) 1127-1132
23. Gupta E., Barends D.M., Yamashita E., Lentz K.A., Harmsze A.M., Shah V.P., Dressman J.B., and Lipper R.A. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur. J. Pharm. Sci. 29 (2006) 315-424
24. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 (2002) 921-925
25. Sun D., Lennernas H., Welage L.S., Barnett J.L., Landowski C.P., Foster D., Fleisher D., Lee K.D., and Amidon G.L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19 (2002) 1400-1416
26. Kasim N.A., Whitehouse M., Ramachandran C., Bermejo M., Lennernas H., Hussain A.S., Junginger H.E., Stavchansky S.A., Midha K.K., Shah V.P., and Amidon G.L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharmacol. 1 (2004) 85-96
27. Petri N., Borga O., Nyberg L., Hedeland M., Bondesson U., and Lennernas H. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 44 (2006) 71-79
28. Lindahl A., Sjoberg A., Bredberg U., Toreson H., Ungell A.L., and Lennernas H. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol. Pharmacol. 1 (2004) 347-356
29. Nyberg L., Mansson W., Abrahamsson B., Seidegard J., and Borga O. A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies. Eur. J. Pharm. Sci. 30 (2007) 432-440
30. Wilding I.I., Hirst P., and Connor A. Development of a new engineering-based capsule for human drug absorption studies. Pharm. Sci. Technol. Today 3 (2000) 385-392
31. Davis S.S., and Wilding I.R. Oral drug absorption studies: the best model for man is man!. Drug Discov. Today 6 (2001) 127-130
32. Ungell A.L., Nylander S., Bergstrand S., Sjoberg A., and Lennernas H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 87 (1998) 360-366
33. Hinderling P.H., Karara A.H., Tao B., Pawula M., Wilding I., and Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J. Clin. Pharmacol. 47 (2007) 19-25
34. Brayden D.J. Controlled release technologies for drug delivery. Drug Discov. Today 8 (2003) 976-978
35. Fagerholm U., Lindahl A., and Lennernas H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J. Pharm. Pharmacol. 49 (1997) 687-690
36. Cao X., Gibbs S.T., Fang L., Miller H.A., Landowski C.P., Shin H.C., Lennernas H., Zhong Y., Amidon G.L., Yu L.X., and Sun D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23 (2006) 1675-1686
37. Bourdet D.L., Pollack G.M., and Thakker D.R. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm. Res. 23 (2006) 1178-1187
38. Bourdet D.L., Pritchard J.B., and Thakker D.R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 315 (2005) 1288-1297
39. Bourdet D.L., and Thakker D.R. Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein. Pharm. Res. 23 (2006) 1165-1177
40. Brayden D.J., Jepson M.A., and Baird A.W. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 10 (2005) 1145-1157
41. Luckey T.D. Introduction to intestinal microecology. Am. J. Clin. Nutr. 25 (1972) 1292-1294
42. Holzapfel W.H., Haberer P., Snel J., Schillinger U., and Huis in't Veld J.H. Overview of gut flora and probiotics. Int. J. Food Microbiol. 41 (1998) 85-101
43. Wong J.M., de Souza R., Kendall C.W., Emam A., and Jenkins D.J. Colonic health: fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40 (2006) 235-243
44. Lindahl A., Sandstrom R., Ungell A.L., Abrahamsson B., Knutson T.W., Knutson L., and Lennernas H. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharmacol. Ther. 60 (1996) 493-503
45. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
46. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., and Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58 (1995) 492-497
47. Cummins C.L., Salphati L., Reid M.J., and Benet L.Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 305 (2003) 306-314
48. Sinko P.J., Leesman G.D., and Amidon G.L. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8 (1991) 979-988
49. Dressman J.B., Amidon G.L., and Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74 (1985) 588-589
50. Benet L.Z., and Cummins C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50 Suppl. 1 (2001) S3-S11
51. Sandstrom R., Knutson T.W., Knutson L., Jansson B., and Lennernas H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br. J. Clin. Pharmacol. 48 (1999) 180-189
52. Tannergren C., Engman H., Knutson L., Hedeland M., Bondesson U., and Lennernas H. St John's wort decreases the bioavailability of R-and S-verapamil through induction of the first-pass metabolism. Clin. Pharmacol. Ther. 75 (2004) 298-309
53. Pinto A.G., Wang Y.H., Chalasani N., Skaar T., Kolwankar D., Gorski J.C., Liangpunsakul S., Hamman M.A., Arefayene M., and Hall S.D. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin. Pharmacol. Ther. 77 (2005) 178-188
54. Berggren S., Gall C., Wollnitz N., Ekelund M., Karlbom U., Hoogstraate J., Schrenk D., and Lennernas H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharmacol. 4 (2007) 252-257
55. Englund G., Jacobson A., Rorsman F., Artursson P., Kindmark A., and Ronnblom A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis. 13 3 (Mar 2007) 291-297
56. Englund G., Rorsman F., Ronnblom A., Karlbom U., Lazorova L., Grasjo J., Kindmark A., and Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29 (2006) 269-277
57. Nakamura T., Sakaeda T., Ohmoto N., Tamura T., Aoyama N., Shirakawa T., Kamigaki T., Nakamura T., Kim K.I., Kim S.R., Kuroda Y., Matsuo M., Kasuga M., and Okumura K. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab. Dispos. 30 (2002) 4-6
58. Thorn M., Finnstrom N., Lundgren S., Rane A., and Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 60 (2005) 54-60
59. Goldin B.R. Intestinal microflora: metabolism of drugs and carcinogens. Ann. Med. 22 (1990) 43-48
60. Rostami-Hodjegan A., and Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6 (2007) 140-148
61. Takada T., Weiss H.M., Kretz O., Gross G., and Sugiyama Y. Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154. Drug Metab. Dispos. 32 (2004) 1272-1278
62. Enokizono J., Kusuhara H., and Sugiyama Y. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab. Dispos. 35 (2007) 209-214
63. I. Ieiri, S. Suwannakul, K. Maeda, H. Uchimaru, K. Hashimoto, M. Kimura, H. Fujino, M. Hirano, H. Kusuhara, S. Irie, S. Higuchi, Y. Sugiyama, SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers, Clin. Pharmacol. Ther. (in press).
64. Bergman E., Forsell P., Tevell A., Persson E.M., Hedeland M., Bondesson U., Knutson L., and Lennernas H. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur. J. Pharm. Sci. 29 (2006) 205-214
65. Ghibellini G., Vasist L.S., Leslie E.M., Heizer W.D., Kowalsky R.J., Calvo B.F., and Brouwer K.L. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin. Pharmacol. Ther. 81 (2007) 406-413
66. Leslie E.M., Watkins P.B., Kim R.B., and Brouwer K.L. Differential inhibition of rat and human Na+ dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by Bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321 (2007) 1170-1178
67. Lande M.B., Donovan J.M., and Zeidel M.L. The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons. J. Gen. Physiol. 106 (1995) 67-84
68. Flynn G.L., Yalkowsky S.H., and Roseman T.J. Mass transport phenomena and models: theoretical concepts. J. Pharm. Sci. 63 (1974) 479-510
69. Fagerholm U., Borgstrom L., Ahrenstedt O., and Lennernas H. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. J. Drug Target. 3 (1995) 191-200
70. Fagerholm U., Nilsson D., Knutson L., and Lennernas H. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. Acta Physiol. Scand. 165 (1999) 315-324
71. Johnson D.A., and Amidon G.L. Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J. Theor. Biol. 131 (1988) 93-106
72. Fagerholm U., Johansson M., and Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13 (1996) 1336-1342
73. Amidon G.L., Sinko P.J., and Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5 (1988) 651-654
74. Kim J.S., Mitchell S., Kijek P., Tsume Y., Hilfinger J., and Amidon G.L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol. Pharmacol. 3 (2006) 686-694
75. Berggren S., Hoogstraate J., Fagerholm U., and Lennernas H. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci. 21 (2004) 553-560
76. Polentarutti B.I., Peterson A.L., Sjoberg A.K., Anderberg E.K., Utter L.M., and Ungell A.L. Evaluation of viability of excised rat intestinal segments in the Ussing chamber: investigation of morphology, electrical parameters, and permeability characteristics. Pharm. Res. 16 (1999) 446-454
77. Winiwarter S., Ax F., Lennernas H., Hallberg A., Pettersson C., and Karlen A. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J. Mol. Graph. Model. 21 (2003) 273-287
78. Corrigan O.I. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. Adv. Exp. Med. Biol. 423 (1997) 111-128
79. Madara J.L., and Pappenheimer J.R. Structural basis for physiological regulation of paracellular pathways in intestinal epithelia. J. Membr. Biol. 100 (1987) 149-164
80. Soergel K.H. Showdown at the tight junction. Gastroenterology 105 (1993) 1247-1250
81. Fagerholm U., and Lennernas H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci. 3 (1995) 247-253
82. Lennernas H., Ahrenstedt O., and Ungell A.L. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. Br. J. Clin. Pharmacol. 37 (1994) 589-596
83. Lennernas H., Nilsson D., Aquilonius S.M., Ahrenstedt O., Knutson L., and Paalzow L.K. The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br. J. Clin. Pharmacol. 35 (1993) 243-250
84. Petri N., Bergman E., Forsell P., Hedeland M., Bondesson U., Knutson L., and Lennernas H. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab. Dispos. 34 (2006) 1182-1189
85. Petri N., Tannergren C., Holst B., Mellon F.A., Bao Y., Plumb G.W., Bacon J., O'Leary K.A., Kroon P.A., Knutson L., Forsell P., Eriksson T., Lennernas H., and Williamson G. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos. 31 (2003) 805-813
86. Sandstrom R., Karlsson A., Knutson L., and Lennernas H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15 (1998) 856-862
87. Tannergren C., Knutson T., Knutson L., and Lennernas H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55 (2003) 182-190
88. Tannergren C., Petri N., Knutson L., Hedeland M., Bondesson U., and Lennernas H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 74 (2003) 423-436
89. Chiu Y.Y., Higaki K., Neudeck B.L., Barnett J.L., Welage L.S., and Amidon G.L. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm. Res. 20 (2003) 749-756
90. Zhang Y., and Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40 (2001) 159-168
91. Petri N., Tannergren C., Rungstad D., and Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 21 (2004) 1398-1404
92. Kalvass J.C., and Pollack G.M. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24 (2007) 265-276
93. Tucker G.T., Houston J.B., and Huang S.M. EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences. Eur. J. Pharm. Sci. 13 (2001) 417-428
94. Huang S.M., Temple R., Throckmorton D.C., and Lesko L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 81 (2007) 298-304
95. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
96. Schulz R., and Winne D. Relationship between antipyrine absorption and blood flow rate in rat jejunum, ileum, and colon. Naunyn-Schmiedeberg's Arch. Pharmacol. 335 (1987) 97-102
97. Lindahl A., Sandstrom R., Ungell A.L., and Lennernas H. Concentration-and region-dependent intestinal permeability of fluvastatin in the rat. J. Pharm. Pharmacol. 50 (1998) 737-744
98. Sandstrom R., Karlsson A., and Lennernas H. The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. J. Pharm. Pharmacol. 50 (1998) 729-735
99. Sandstrom R., and Lennernas H. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. Drug Metab. Dispos. 27 (1999) 951-955
100. Brasitus T.A., and Dudeja P.K. Regional differences in the lipid composition and fluidity of rat colonic brush-border membranes. Biochim. Biophys. Acta 819 (1985) 10-17
101. Brasitus T.A., and Dudeja P.K. Alterations in the physical state and composition of brush border membrane lipids of rat enterocytes during differentiation. Arch. Biochem. Biophys. 240 (1985) 483-488
102. Fagerholm U., Sjostrom B., Sroka-Markovic J., Wijk A., Svensson M., and Lennernas H. The effect of a drug-delivery system consisting of soybean phosphatidyl choline and medium-chain monoacylglycerol on the intestinal permeability of hexarelin in the rat. J. Pharm. Pharmacol. 50 (1998) 467-473
103. Stein W.D. Quantitative relationships between the measurable transport resistances of membrane carriers: theory and experiment. Biochim. Biophys. Acta 856 (1986) 634-639
104. Lindahl A., Krondahl E., Gruden A.C., Ungell A.L., and Lennernas H. Is the jejunal permeability in rats age-dependent?. Pharm. Res. 14 (1997) 1278-1281
105. Berggren S., Lennernas P., Ekelund M., Westrom B., Hoogstraate J., and Lennernas H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J. Pharm. Pharmacol. 55 (2003) 963-972
106. Lindell M., Karlsson M.O., Lennernas H., Pahlman L., and Lang M.A. Variable expression of CYP and Pgp genes in the human small intestine. Eur. J. Clin. Investig. 33 (2003) 493-499
107. Lindell M., Lang M., and Lennernas H. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur. J. Drug Metab. Pharmacokinet. 28 (2003) 41-48
108. Krondahl E., Tronde A., Eirefelt S., Forsmo-Bruce H., Ekstrom G., Bengtsson U.H., and Lennernas H. Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract. Peptides 23 (2002) 479-488
109. Chiou W.L., and Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15 (1998) 1792-1795
110. Chiou W.L., Ma C., Chung S.M., Wu T.C., and Jeong H.Y. Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int. J. Clin. Pharmacol. Ther. 38 (2000) 532-539
111. Makhey V.D., Guo A., Norris D.A., Hu P., Yan J., and Sinko P.J. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res. 15 (1998) 1160-1167
112. Yuasa H., Matsuda K., and Watanabe J. Influence of anesthetic regimens on intestinal absorption in rats. Pharm. Res. 10 (1993) 884-888
113. Chadwick V.S., Phillips S.F., and Hofmann A.F. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). II. Application to normal and abnormal permeability states in man and animals. Gastroenterology 73 (1977) 247-251
114. Chadwick V.S., Phillips S.F., and Hofmann A.F. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400. Gastroenterology 73 (1977) 241-246
115. Artursson P., Ungell A.L., and Lofroth J.E. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. 10 (1993) 1123-1129
116. Hollander D., Koyama S., Dadufalza V., Tran D.Q., Krugliak P., Ma T., and Ling K.Y. Polyethylene glycol 900 permeability of rat intestinal and colonic segments in vivo and brush border membrane vesicles in vitro. J. Lab. Clin. Med. 113 (1989) 505-515
117. Krugliak P., Hollander D., Schlaepfer C.C., Nguyen H., and Ma T.Y. Mechanisms and sites of mannitol permeability of small and large intestine in the rat. Dig. Dis. Sci. 39 (1994) 796-801
118. Stephens R.H., O'Neill C.A., Warhurst A., Carlson G.L., Rowland M., and Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296 (2001) 584-591
119. Sababi M., Borga O., and Hultkvist-Bengtsson U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur. J. Pharm. Sci. 14 (2001) 21-27
120. Fricker G., Drewe J., Huwyler J., Gutmann H., and Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118 (1996) 1841-1847
121. van de Kerkhof E.G., Ungell A.L., Sjoberg A.K., de Jager M.H., Hilgendorf C., de Graaf I.A., and Groothuis G.M. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Metab. Dispos. 34 (2006) 1893-1902
122. Collett A., Tanianis-Hughes J., Carlson G.L., Harwood M.D., and Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur. J. Pharm. Sci. 26 (2005) 386-393
123. Gramatte T., el Desoky E., and Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur. J. Clin. Pharmacol. 46 (1994) 253-259
124. Gramatte T. Griseofulvin absorption from different sites in the human small intestine. Biopharm. Drug Dispos. 15 (1994) 747-759
125. Gramatte T., and Richter K. Paracetamol absorption from different sites in the human small intestine. Br. J. Clin. Pharmacol. 37 (1994) 608-611
126. Usansky H.H., and Sinko P.J. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J. Pharmacol. Exp. Ther. 314 (2005) 391-399
127. Chiou W.L., Chung S.M., Wu T.C., and Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39 (2001) 93-101
128. Schwarz U.I., Hanso H., Oertel R., Miehlke S., Kuhlisch E., Glaeser H., Hitzl M., Dresser G.K., Kim R.B., and Kirch W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 81 (2007) 669-678
129. Kunta J.R., and Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. 5 (2004) 109-124
130. Glaeser H., Bailey D.G., Dresser G.K., Gregor J.C., Schwarz U.I., McGrath J.S., Jolicoeur E., Lee W., Leake B.F., Tirona R.G., and Kim R.B. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81 (2007) 362-370
131. Sutton S.C., Evans L.A., Fortner J.H., McCarthy J.M., and Sweeney K. Dog colonoscopy model for predicting human colon absorption. Pharm. Res. 23 (2006) 1554-1563
132. Sutton S.C. Companion animal physiology and dosage form performance. Adv. Drug Deliv. Rev. 56 (2004) 1383-1398
133. Lui C.Y., Amidon G.L., Berardi R.R., Fleisher D., Youngberg C., and Dressman J.B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 75 (1986) 271-274
134. He Y.L., Murby S., Warhurst G., Gifford L., Walker D., Ayrton J., Eastmond R., and Rowland M. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and d-peptides. J. Pharm. Sci. 87 (1998) 626-633
135. Fotaki N., Symillides M., and Reppas C. Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration. Eur. J. Pharm. Sci. 26 (2005) 324-333
136. Collett A., Walker D., Sims E., He Y.L., Speers P., Ayrton J., Rowland M., and Warhurst G. Influence of morphometric factors on quantitation of paracellular permeability of intestinal epithelia in vitro. Pharm. Res. 14 (1997) 767-773
137. Davis J.L., Little D., Blikslager A.T., and Papich M.G. Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. J. Vet. Pharmacol. Ther. 29 (2006) 379-385
138. Olsen L., Ingvast-Larsson C., Larsson P., Brostrom H., Bondesson U., Sundqvist M., and Tjalve H. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. J. Vet. Pharmacol. Ther. 29 (2006) 129-135
139. Lennernäs H., Fagerholm U., Raab Y., Gerdin B., and Hällgren R. Regional rectal perfusion, a new in vivo approach to study rectal drug absorption in man. Pharm. Res. 12 (1995) 426-432
140. Söderholm J.D., Olaison G., Kald A., Tagesson C., and Sjödahl R. Absorption profiles for polyethylene glycols after regional jejunal perfusion and oral load in healthy humans. Dig. Dis. Sci. 42 4 (Apr 1997) 853-857
141. Lennernäs H., Nylander S., and Ungell A.-L. Correlation of effective drug permeability measurements in vitro using the Ussing chamber and the human jejunal perfusion. Pharm. Res. 14 (1997) 667-671
142. Lennernäs H. Human intestinal permeability: An overview. J. Pharm. Sci. 87 (1998) 403-410
143. Riley S.A., Kim M., Sutcliffe F., Kapas M., Rowland M., and Turnberg L.A. Effects of a non-absorbable osmotic load on drug absorption in healthy volunteers. Br. J. Clin. Pharmacol. 34 (1992) 40-46
144. Riley S.A., Sutcliffe F., Kim M., Kapas M., Rowland M., and Turnberg L.A. The influence of gastrointestinal transit on drug absorption in healthy volunteers. Br. J. Clin. Pharmacol. 34 (1992) 32-39
145. Lennernäs H., Nylander S., and Ungell A.-L. Correlation of effective drug permeability measurements in vitro using the Ussing chamber and the human jejunal perfusion. Pharm. Res. 14 (1997) 667-671